363 related articles for article (PubMed ID: 32533428)
1. What predicts pharmacists' engagement with opioid-outcome screening? Secondary analysis from an implementation study in community pharmacy.
Nielsen S; Sanfilippo P; Picco L; Bruno R; Kowalski M; Wood P; Larney S
Int J Clin Pharm; 2021 Apr; 43(2):420-429. PubMed ID: 32533428
[TBL] [Abstract][Full Text] [Related]
2. Routine opioid outcome monitoring in community pharmacy: Outcomes from an open-label single-arm implementation-effectiveness pilot study.
Nielsen S; Picco L; Kowalski M; Sanfilippo P; Wood P; Larney S; Bruno R; Ritter A
Res Social Adm Pharm; 2020 Dec; 16(12):1694-1701. PubMed ID: 32273255
[TBL] [Abstract][Full Text] [Related]
3. Routine opioid outcome monitoring in community pharmacy: Pilot implementation study protocol.
Nielsen S; Kowalski M; Wood P; Larney S; Bruno R; Shanahan M; Lenton S; Dietze P; Green T; Murnion B; Ritter A
Res Social Adm Pharm; 2019 Aug; 15(8):1047-1055. PubMed ID: 30396825
[TBL] [Abstract][Full Text] [Related]
4. Patient and pharmacist perspectives on opioid misuse screening and brief interventions in community pharmacies.
Rao D; Ford JH; Shiyanbola OO
Addict Sci Clin Pract; 2024 Apr; 19(1):27. PubMed ID: 38589965
[TBL] [Abstract][Full Text] [Related]
5. Pharmacists' naloxone services beyond community pharmacy settings: A systematic review.
Rawal S; Osae SP; Cobran EK; Albert A; Young HN
Res Social Adm Pharm; 2023 Feb; 19(2):243-265. PubMed ID: 36156267
[TBL] [Abstract][Full Text] [Related]
6. Naloxone for opioid overdose prevention: pharmacists' role in community-based practice settings.
Bailey AM; Wermeling DP
Ann Pharmacother; 2014 May; 48(5):601-6. PubMed ID: 24523396
[TBL] [Abstract][Full Text] [Related]
7. Stocking and supplying naloxone: Findings from a representative sample of community pharmacies in Victoria, Australia.
Karthikeyan N; Xia T; Nielsen S; Picco L
Drug Alcohol Rev; 2024 Jul; 43(5):1305-1312. PubMed ID: 38691509
[TBL] [Abstract][Full Text] [Related]
8. Implementation of a mental health medication management intervention in Australian community pharmacies: Facilitators and challenges.
Hattingh HL; Kelly F; Fowler J; Wheeler AJ
Res Social Adm Pharm; 2017; 13(5):969-979. PubMed ID: 28583302
[TBL] [Abstract][Full Text] [Related]
9. Patient, family members and community pharmacists' views of a proposed overdose prevention intervention delivered in community pharmacies for patients prescribed high-strength opioids for chronic non-cancer pain: An explorative intervention development study.
Mercer F; Parkes T; Foster R; Steven D; McAuley A; Baldacchino A; Steele W; Schofield J; Matheson C
Drug Alcohol Rev; 2023 Mar; 42(3):517-526. PubMed ID: 36165733
[TBL] [Abstract][Full Text] [Related]
10. Preparing pharmacists to increase naloxone dispensing within community pharmacies under the Pennsylvania standing order.
Santa HM; Amirova SG; Ventricelli DJ; Downs GE; Nowalk AA; Pringle JL; Aruru M
Am J Health Syst Pharm; 2021 Feb; 78(4):327-335. PubMed ID: 33336254
[TBL] [Abstract][Full Text] [Related]
11. Attitudes and availability: A comparison of naloxone dispensing across chain and independent pharmacies in rural and urban areas in Alabama.
Sisson ML; McMahan KB; Chichester KR; Galbraith JW; Cropsey KL
Int J Drug Policy; 2019 Dec; 74():229-235. PubMed ID: 31698165
[TBL] [Abstract][Full Text] [Related]
12. Implementation of diabetes screening in community pharmacy - factors influencing successful implementation.
Siu AHY; Krass I; Mitchell B; McNamara K
Res Social Adm Pharm; 2021 Sep; 17(9):1606-1613. PubMed ID: 33414090
[TBL] [Abstract][Full Text] [Related]
13. Atrial fibrillation screening in pharmacies using an iPhone ECG: a qualitative review of implementation.
Lowres N; Krass I; Neubeck L; Redfern J; McLachlan AJ; Bennett AA; Freedman SB
Int J Clin Pharm; 2015 Dec; 37(6):1111-20. PubMed ID: 26202627
[TBL] [Abstract][Full Text] [Related]
14. Community pharmacist knowledge, attitudes and confidence regarding naloxone for overdose reversal.
Nielsen S; Menon N; Larney S; Farrell M; Degenhardt L
Addiction; 2016 Dec; 111(12):2177-2186. PubMed ID: 27367125
[TBL] [Abstract][Full Text] [Related]
15. Implementation and assessment of a pilot, community pharmacy-based, opioid pain medication management program.
Manzur V; Mirzaian E; Huynh T; Lien A; Ly K; Wong H; Wang M; Lou M; Durham M
J Am Pharm Assoc (2003); 2020; 60(3):497-502. PubMed ID: 31926871
[TBL] [Abstract][Full Text] [Related]
16. The influence of pharmacy and pharmacist characteristics on the secondary prevention of cardiovascular disease.
Puspitasari HP; Aslani P; Krass I
Int J Clin Pharm; 2015 Oct; 37(5):834-43. PubMed ID: 25964140
[TBL] [Abstract][Full Text] [Related]
17. Assessing pharmacists' readiness to dispense naloxone and counsel on responding to opioid overdoses.
Melaragni F; Levy C; Pedrazzi J; Andersen M
J Am Pharm Assoc (2003); 2019; 59(4):550-554.e2. PubMed ID: 31109812
[TBL] [Abstract][Full Text] [Related]
18. Identifying barriers to dispensing naloxone: A survey of community pharmacists in North Carolina.
Rudolph SE; Branham AR; Rhodes LA; Hayes HH; Moose JS; Marciniak MW
J Am Pharm Assoc (2003); 2018; 58(4S):S55-S58.e3. PubMed ID: 30006187
[TBL] [Abstract][Full Text] [Related]
19. Using the behaviour change wheel to understand and address barriers to pharmacy naloxone supply in Australia.
Nielsen S; Olsen A
Int J Drug Policy; 2021 Apr; 90():103061. PubMed ID: 33321285
[TBL] [Abstract][Full Text] [Related]
20. Feasibility and acceptability of a proposed pharmacy-based harm reduction intervention to reduce opioid overdose, HIV and hepatitis C.
Meyerson BE; Agley JD; Jayawardene W; Eldridge LA; Arora P; Smith C; Vadiei N; Kennedy A; Moehling T;
Res Social Adm Pharm; 2020 May; 16(5):699-709. PubMed ID: 31611071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
